Liminatus Pharma (LIMN) Short-Term Debt issuances (2024 - 2025)
Liminatus Pharma (LIMN) posted Short-Term Debt issuances of $3.0 million for Q4 2025, up 417.89% sequentially from $587000.0 in Q2 2025, and up 334.29% YoY from $700000.0 in Q4 2024.
Liminatus Pharma (LIMN) Short-Term Debt issuances (2024 - 2025) Analysis & Trends
Liminatus Pharma has reported Short-Term Debt issuances for 2 years, with the latest figure at $3.0 million in Q4 2025.
- Quarterly Short-Term Debt issuances rose 334.29% year-over-year to $3.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.3 million (changed N/A YoY) and the FY2025 annual result came in at $4.3 million, up 10.63% from the prior year.
- Short-Term Debt issuances improved to $3.0 million in Q4 2025 per LIMN's latest filing, from $587000.0 in the prior quarter.
- Over five years, Short-Term Debt issuances peaked at $3.0 million in Q4 2025 and troughed at $587000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Liminatus Pharma | 256.03 Mn | 256.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.04 Mn |
| Dec 31, 2025 | 3.04 Mn |
| Jun 30, 2025 | 587,000.00 |
| Jun 30, 2025 | 587,000.00 |
| Mar 31, 2025 | 713,000.00 |
| Mar 31, 2025 | 713,000.00 |
| Dec 31, 2024 | 700,000.00 |
| Dec 31, 2024 | 700,000.00 |
| Sep 30, 2024 | 983,000.00 |
| Sep 30, 2024 | 983,000.00 |